Novo Nordisk A/S purchases B shares worth DKK 5,428 million from Novo Holdings A/S under the 2024 share repurchase programme

Bagsværd, Denmark, 06 May 2024 – Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 5,427,801,225.00 million from Novo Holdings A/S. The transaction is part of Novo Nordisk A/S’ 2024 share repurchase programme of up to a total of DKK 20 billion to be executed during a 12-month period beginning 6 February 2024. The transaction price is DKK 860.02 per share and has been calculated as the three-day volume weighted average market price from 2 May 2024 to 6 May 2024 in the open window following the announcement of Novo Nordisk A/S’ quarterly financial results.

Prior to the sale of B shares, Novo Holdings A/S’ ownership of Novo Nordisk A/S was 28.3% of the share capital and 77.4% of the votes. Following the transaction, Novo Holdings A/S owns 1,074,872,000 A shares of DKK 0.10 and 183,871,750 B shares of DKK 0.10, corresponding to 28.2% of the capital and 77.3% of the votes in Novo Nordisk A/S.

The transaction is in line with the announcement on 31 January 2024 that Novo Holdings A/S intends to maintain its ownership of Novo Nordisk A/S’ share capital around 28%.

In addition, transactions related to Novo Nordisk’s incentive programmes have resulted in a net transfer from Novo Nordisk of 93,461 B shares in the period from 2 May 2024 to 6 May 2024.

With the transactions stated above, Novo Nordisk A/S owns a total of 10,163,508 B shares of DKK 0.10, corresponding to 0.2% of the share capital, as treasury shares. The total number of A and B shares in the company is 4,465,000,000 of DKK 0.10 including treasury shares.

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases, built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 66,000 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Instagram, X, LinkedIn and YouTube.

Contacts for further information

Media:
Ambre James-Brown +45 3079 9289abmo@novonordisk.com	Liz Skrbkova (US)+1 609 917 0632lzsk@novonordisk.com
Investors:
Daniel Muusmann Bohsen+45 3075 2175 dabo@novonordisk.com	Jacob Martin Wiborg Rode+45 3075 5956jrde@novonordisk.com
David Heiberg Landsted +45 3077 6915 dhel@novonordisk.com	Mark Joseph Root (US) +1 848 213 3219mjhr@novonordisk.com
Sina Meyer +45 3079 6656azey@novonordisk.com	Frederik Taylor Pitter +45 3075 8259fptr@novonordisk.com
Ida Melvold Gjøsund+45 3077 5649 idmg@novonordisk.com